ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

linsitinib

Also written as “OSI-906” and “Linsitinib”.

Its studies are mostly in Graves Ophthalmopathy · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Adrenocortical Carcinoma · Carcinoma, Hepatocellular, led by 2 companies.

Drug pageLinsitinib: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 17, 200913 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma100 open or runningphase 3since Jun 17, 2009Aug 7, 2007none ahead
Sling Therapeuticsits history only32 open or runningphase 3since Mar 2, 2022Mar 2, 2022Jun 30, 2028phase 3 · NCT07753603

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Astellas Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2007First studies: 2 phase 1 studiesFirst studyNCT00514306, NCT00514007
  2. Aug 19, 2008Phase 1 study in Pancreatic NeoplasmsNCT00739453 · 95 enrolled · United States, United Kingdom
  3. Apr 6, 2009Phase 2 study in Ovarian NeoplasmsNCT00889382 · 152 enrolled · United States, Australia, Canada and more
  4. Jun 17, 2009Phase 3 study in Adrenocortical CarcinomaNCT00924989 · 139 enrolled · United States, Australia, Canada and more
  5. Apr 8, 2010Phase 2 study in Carcinoma, HepatocellularNCT01101906 · 23 enrolled · United States, Belgium, France and more
  6. Aug 19, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01186861 · 205 enrolled · United States, Brazil, Canada and more
  7. Oct 5, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01221077 · 88 enrolled · United States, Canada, Hong Kong and more
  8. Feb 7, 2012Phase 1 study in NeoplasmsNCT01529684 · 5 enrolled · United States
  9. Feb 5, 2014Phase 2 study in Advanced Solid TumorsNCT02057380 · 13 enrolled · United States, Brazil, Czechia and more

TargetBeta

IGF1R →INSR →read by rule
“An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor”ChEMBL 37, by rule

Studies

All 10 Astellas Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02057380Advanced Solid Tumors · United States, Brazil, Czechia and more2CompletedOct 14, 201613
NCT01529684Neoplasms · United States1CompletedDec 8, 20125
NCT01221077Carcinoma, Non-Small-Cell Lung · United States, Canada, Hong Kong and more2CompletedMar 1, 201388
NCT01186861Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more2CompletedJul 1, 2013205
NCT01101906Carcinoma, Hepatocellular · United States, Belgium, France and more2TerminatedNov 4, 201123
NCT00924989Adrenocortical Carcinoma · United States, Australia, Canada and more3CompletedJul 11, 2012139
NCT00889382Ovarian Neoplasms · United States, Australia, Canada and more2CompletedAug 1, 2014152
NCT00739453Pancreatic Neoplasms · United States, United Kingdom1CompletedMar 3, 201295
NCT00514306Ovarian Neoplasms · United States, United Kingdom1CompletedSep 20, 201079
NCT00514007Colorectal Neoplasms · United States, United Kingdom1CompletedMar 19, 201295

How it is read

Names in the registry

  • “OSI-906”, 9 entries
  • “linsitinib”, 3 entries
  • “Linsitinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.